Latest Regulatory News

Wrkr Ltd has completed a $15 million placement to fund key growth initiatives and compliance upgrades ahead of new superannuation regulations.

Liontown Resources has raised approximately A$316 million through a combination of institutional and conditional placements, alongside a share purchase plan, to strengthen its balance sheet and support growth at its Kathleen Valley lithium operation.

PointsBet’s board has unanimously recommended shareholders accept MIXI Australia’s increased $1.25 per share cash offer, now unconditional and representing a significant premium. MIXI holds 28.2% of PointsBet and may raise the offer further if it gains majority control.

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.

Magnetite Mines Limited has announced a pro rata renounceable rights issue aiming to raise up to $2.65 million to advance its flagship Razorback iron ore project. The capital raise includes free attaching options and is partially underwritten, supporting key development milestones and strategic partnerships.

Rewardle Holdings Limited reported a 2.8% revenue increase to $9.68 million for FY24 but swung to a $3.44 million net loss, driven by rising expenses and associate losses. The company expanded its footprint with acquisitions in grocery delivery and fintech, while deepening its stake in AI-powered health tech partner CloudHolter.

Magnetite Mines Limited has updated its Razorback Iron Ore Project, revealing a 6.6 billion tonne mineral resource and progressing key strategic partnerships and approvals to support green steelmaking ambitions.

Magnetite Mines Limited has announced a renounceable rights issue to raise up to $2.65 million, aiming to fund critical development milestones for its Razorback Iron Ore Project and secure strategic partnerships for DFS funding.

Thunderbird Resources has addressed a recent spike in its share price and volume by releasing previously undisclosed survey results following a trading halt, reaffirming its compliance with ASX rules.

Elders Limited faces a regulatory delay from the ACCC on its acquisition of Delta Agribusiness but remains optimistic about the deal's benefits and completion timeline.

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.